HIV Diagnostics Market Research Report Outlook 2019 -2027 Resilience and Reinvention in a Changing Marketplace with Size, Share, Growth, Technology, By Diagnosis, Treatment, End-User | CMI

Acquired Immunodeficiency Syndrome (AIDS) is caused by the human immunodeficiency virus (HIV). In this condition, HIV destroys the CD4 T lymphocytes cells of the immune system and reduces the ability of the body to fight against infections. It can be diagnosed by using various tests such as blood tests, saliva tests, viral load tests, though the most efficient test results are obtained by Enzyme-Linked Immunosorbent Assay (ELISA) test initially and later by Western Bloat Method. According to WHO, the HIV diagnosis includes free-standing sites, testing services in health care facilities, some community-based approaches and HIV self-testing (HIVST).

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/422

Rising Government initiatives in order to reduce the incidence of AIDS is propelling the growth of HIV Diagnostics Marketincreasing prevalence of HIV/AIDS globally and governmental initiatives to generate awareness regarding HIV in people has fueled the growth of the HIV Diagnostic Market.

The government of various countries is taking various initiatives to reduce the incidences of disease. According to the WHO report, 2015, there is a 0.8% prevalence of HIV globally and Sab-Saharan Africa remains the most severely affected area with 70% of people for the global population. For instance, the unmet requirements in Asia and Africa region for HIV diagnosis, and the government initiatives taken in the region may drive the market for HIV diagnostics.

The advent of HIV rapid diagnostics test proved to be important for obtaining the early results

Rising demand for early diagnosis of HIV in order to reduce the mortality rate and rapid initiation of the treatments such as Virological testing using nucleic acid testing (NAT) technology is projected to boost market growth.

Antibody test segment is accounting for the largest segment because of its extremely accurate results, among the HIV diagnostics market

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/422

North America to witness the major share owing to expanding HIV diagnostic centers over the forecast period

The global HIV diagnostics market by region comprises North America, Asia Pacific, South Africa, Europe and the rest of the world. North America dominates the HIV diagnostics market owing to supportive government initiatives and funding in order to improve HIV diagnosis procedures and raise awareness regarding HIV among the population and an increase in demand for HIV diagnosis products in North America. For the North-America region, the US government is allocating a significant budget for research and development in the area of HIV/AIDS diagnosis and favorable reimbursement policies in the region for encouraging the people to take the HIV diagnostics test which is driving the HIV diagnostics market in this region.

Asia Pacific is an emerging market for HIV diagnostics, and this can be attributed to the growing patient population suffering from HIV/AIDS and to generate awareness among the population is pulling the HIV diagnostics market for this region.

The rising number of clinical research and development by an industry player to boost the growth of HIV diagnostics market

Competitive Landscape

The key players operating the HIV Diagnostics Market globally are Abbott Healthcare, BD Biosciences, Roche Diagnostics, Zyomyx Incorporation, Merck & Company Incorporation, Bristol –Myres Squibb, Janssen Therapeutic, Hologic Incorporation, Chembio Diagnostic Systems, Alere Incorporation, Sysmex Incorporation Gilead Sciences, Qiagen,  VIIV healthcare, Beckman Coulter  And many others. To increase the accessibility and portability major market players are involved in the clinical research of CD4, antibody test, and viral load testing in the HIV diagnostics market.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/market-insight/hiv-diagnostics-market-422

Key Development

• In July 2019, Mylan N.V. and Atomo Diagnostics announced that the Mylan HIV Self-Test received a prequalification approval by the World Health Organization (WHO PQ).
• In February 2019, Hologic, Inc., a leading medical technology company, launched Aptima HIV-1 Quant Dx Assay, which is a one-of-its-kind dual-claim the assay used for early infant diagnosis (EID) and viral load (VL).
• In 2018, Abbott launched a new point-of-care test called m-PIMA HIV-1/2 VL for management of human immunodeficiency virus (HIV) infection in The Netherlands.
• In 2018, Owned Mumford launched Simplitude Pro HIV rapid diagnostic test in Europe for the diagnosis of HIV.
• In 2014, BD Biosciences, a segment of BD (Becton, Dickinson, and Company), launched BD FACSPresto near-patient CD4 counter system for HIV/AIDS patients, which provide lymphocytes and hemoglobin (Hb) concentration in blood samples to stage and monitor HIV/AIDS patients.

Read Press Release: https://www.coherentmarketinsights.com/press-release/hiv-diagnostics-market-2773

Market-Taxonomy

The global HIV Diagnosis Market is segmented on the basis of product type, end-user and region

By Product Type

• Antibody test
• HIV-1 test
• HIV-1 antibody confirmatory test
• HIV-2 and O diagnostics test
• Viral Identification Assays
• P24 antigen test
• Qualitative PCR test
• Viral Culture
• CD4 testing
• Viral load testing
• Early Infant diagnostics

By End-User

• Hospitals
• Diagnostics Laboratories
• Blood banks
• Home care settings
• Others (cell bank, Gene bank, Biotechnology, and pharma companies)

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.